A large number of cytokines involved in inflammation are being targeted by specific antagonists for the treatment of chronic, T cell-mediated inflammatory diseases (Table 18-5). The first success with this class of biologic agents came with a soluble form of the TNF receptor and anti-TNF antibodies, which bind to and neutralize TNF. These agents are of great benefit in many patients with rheumatoid arthritis, Crohn's disease, and the skin disease psoriasis. Antagonists of other proinflammatory cytokines, such as IL-1, the p40 chain that is present in both IL-12 and IL-23, IL-6, IL-17A, and many others, are in use or in clinical trials for inflammatory diseases.
Was this article helpful?